PDF(Pubmed)
Abstract：
Treatment of multiple myeloma (MM) has evolved remarkably over the past few decades. Autologous stem cell transplantation, as well as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has substantially improved the prognosis of patients with MM. Novel therapies, including chimeric antigen receptor-T cells, bispecific T-cell engagers, antibody-drug conjugates, histone deacetylase inhibitors, and nuclear export inhibitors, have provided more options. However, MM remains incurable. T cells are the principal weapons of antitumor immunity, but T cells display a broad spectrum of dysfunctional states during MM. The promising clinical results of T-cell-directed immunotherapies emphasize the significance of enhancing T-cell function in antimyeloma treatment. This review summarizes the potential effects of these antimyeloma agents on T-cell function and discusses possible optimized strategies for MM management by boosting T-cell immunity.
摘要：
在过去的几十年中，多发性骨髓瘤（MM）的治疗取得了显着进展。自体干细胞移植,以及蛋白酶体抑制剂，免疫调节药物，和单克隆抗体，大大改善了MM患者的预后。新疗法,包括嵌合抗原受体T细胞，双特异性T细胞衔接者，抗体-药物缀合物，组蛋白去乙酰化酶抑制剂，和核出口抑制剂，提供了更多的选择。然而,MM仍然无法治愈。T细胞是抗肿瘤免疫的主要武器,但是T细胞在MM期间表现出广泛的功能失调状态。T细胞定向免疫疗法的有希望的临床结果强调了增强T细胞功能在抗骨髓瘤治疗中的重要性。这篇综述总结了这些抗白血病药物对T细胞功能的潜在影响，并讨论了通过增强T细胞免疫来管理MM的可能优化策略。
